Hedner T
Department of Clinical Pharmacology, Sahlgrenska University Hospital, Göteborg, Sweden.
Blood Press Suppl. 2000;2:4-6.
Since most developed countries have an ageing population, the prevalence of hypertension is increasing. This age-driven increase in cardiovascular risk is an important factor contributing to the increasing burden of mortality and morbidity associated with cardiovascular disease. Today, there is a strong rationale for an aggressive approach to hypertension since antihypertensive treatment has been shown to reduce cardiovascular mortality and morbidity in the elderly. It is likely that increasing emphasis will be placed on control of isolated and borderline systolic hypertension, which are the predominant forms of hypertension in elderly patients. The recent second Swedish Trial in Old Patients with Hypertension (STOP-Hypertension-2) represents an important contribution to the literature since it shows that newer antihypertensive agents, such as angiotensin converting enzyme (ACE) inhibitors and calcium antagonists, are as effective as older agents in reducing cardiovascular mortality and morbidity in elderly patients.
由于大多数发达国家的人口老龄化，高血压的患病率正在上升。这种由年龄驱动的心血管风险增加是导致与心血管疾病相关的死亡率和发病率负担不断增加的一个重要因素。如今，积极治疗高血压有充分的理由，因为抗高血压治疗已被证明可降低老年人的心血管死亡率和发病率。很可能会更加重视单纯收缩期高血压和临界收缩期高血压的控制，这两种是老年患者高血压的主要形式。最近的第二项瑞典老年高血压患者试验（STOP-Hypertension-2）对该领域文献作出了重要贡献，因为它表明新型抗高血压药物，如血管紧张素转换酶（ACE）抑制剂和钙拮抗剂，在降低老年患者心血管死亡率和发病率方面与传统药物同样有效。
